Biopharmaceutical company TFF Pharmaceuticals Inc (NASDAQ:TFFP) reported on Thursday that the last subject in the multiple ascending dose (MAD) portion of its Phase 1 clinical trial of Voriconazole Inhalation Powder has completed their last clinic visit, following repeated dosing.
Voriconazole Inhalation Powder is a next-generation, direct-to-lung, inhaled dry powder version of Voriconazole, an antifungal drug for treating Invasive Pulmonary Aspergillosis (IPA). In the trial, repeated doses of up to 80mg/dose twice daily for seven days in healthy volunteers were well tolerated.
The single ascending dose (SAD) and MAD phases, with 32 participants in each stage, were conducted to evaluate the safety, tolerability and pharmacokinetic profile of Voriconazole Inhalation Powder.
TFF Pharmaceuticals' proprietary Thin Film Freezing (TFF) technology platform allows the reformulation of Voriconazole into dry powder particles to directly target the site of the fungal infection in the lung.
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
ACG to invest USD200m in US hard-shell capsule manufacturing
Charles River and X-Chem form strategic collaboration to accelerate hit identification
Merck reports long-term survival benefits of Keytruda in non-small cell lung cancer
Avacta reports promising Phase 1a data for faridoxorubicin at ESMO 2025